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ABSTRACT
Ewing’s sarcoma (ES) is the second most common bone cancer in children and 
young people. Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) 
is the prototype of a family of synthetic antitumor compounds, collectively known as 
alkylphospholipid analogs (APLs). We have found that APLs ranked edelfosine>pe
rifosine>erucylphosphocholine>miltefosine for their capacity to promote apoptosis 
in ES cells. Edelfosine accumulated in the endoplasmic reticulum (ER) and triggered 
an ER stress response that eventually led to caspase-dependent apoptosis in ES 
cells. This apoptotic response involved mitochondrial-mediated processes, with 
cytochrome c release, caspase-9 activation and generation of reactive oxygen species. 
Edelfosine-induced apoptosis was also dependent on sustained c-Jun NH2-terminal 
kinase activation. Oral administration of edelfosine showed a potent in vivo antitumor 
activity in an ES xenograft animal model. Histochemical staining gave evidence for 
ER stress response and apoptosis in the ES tumors isolated from edelfosine-treated 
mice. Edelfosine showed a preferential action on ES tumor cells as compared to non-
transformed osteoblasts, and appeared to be well suited for combination therapy 
regimens. These results demonstrate in vitro and in vivo antitumor activity of 
edelfosine against ES cells that is mediated by caspase activation and ER stress, 
and provide the proof of concept for a putative edelfosine- and ER stress-mediated 
approach for ES treatment.
INTRODUCTION
Ewing’s sarcoma (ES) is the third most frequent 
primary bone cancer, and the second most common, 
after osteosarcoma, in children, adolescents, and young 
adults. ES tumors primarily affect children and teenagers, 
represent almost 3% of pediatric cancers with a peak 
incidence between the ages of 10 and 15, and are rarely 
seen in children younger than 5 or adults older than 30 
[1-3]. ES is considered a rare disease with an estimated 
annual incidence of 0.6-2.9 per million population, and 
the natural course of the disease is rapid dissemination and 
death from metastases within 1-2 years from diagnosis [4].
ES is a member of Ewing’s family tumors (ESFT) 
and it is associated in 85-90% of cases with the t(11;22)
(q24:q12) chromosomal translocation that generates 
fusion of the 5’ segment of the EWS gene with the 3’ 
segment of the ETS family gene FLI-1. The resulting 
EWS-FLI-1 fusion protein alters transcriptional activity 
and modulates the expression of a number of downstream 
target genes relevant to apoptosis, proliferation, and neural 
differentiation, leading to aberrant transcription that 
promotes tumor initiation and propagation via prosurvival 
and antiapoptotic pathways [2, 5].
ES has a high metastatic proclivity and is typically 
refractory to conventional chemo- and radiation therapy. 
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The prognosis of children and young adults with metastatic 
or recurrent disease is poor, with less than one-third of 
patients with metastases at diagnosis and only 10% of 
patients with recurrent disease being long-term survivors 
[6, 7]. The presence of cancer stem cells in ES might be, at 
least in part, responsible for refractory responses to current 
chemotherapies as well as for the aggressive behavior and 
high tendency to early metastasis and relapse of the disease 
[8, 9]. With modern multimodal regimens consisting of 
local surgery and/or radiotherapy plus intensive systemic 
chemotherapy, survival can be achieved for ~70% of 
patients with localized disease, but a relapse of ~30% 
leads to unfavorable prognosis [10]. However, despite 
advances in diagnosis and multidisciplinary treatment, the 
5-year survival of ES patients with metastatic or recurrent 
disease remains less than 25% [10, 11], with patients 
with isolated lung metastases having better prognosis 
(30% at 5 years) than those with bone or bone marrow 
metastases (≤20% at 5 years) [4]. Thus, search for new 
chemotherapeutic agents are urgently needed to improve 
clinical outcome. Microarray, miRNA and functional 
studies suggest that ES tumors with poor prognosis show 
resistance to apoptosis [12-16], which might constitute 
one of the major mechanisms in tumor progression and 
chemoresistance. On these grounds, triggering of the 
cancer cell apoptotic machinery constitutes an appealing 
approach to combat ES [17].
The alkylphospholipid analogs (APLs) represent 
a number of structurally related compounds that show 
antitumor activity against several tumor cells by affecting 
signaling processes at the membrane level [18-21]. Among 
the distinct APLs, miltefosine is already in clinical use 
as a topical cytostatic drug for palliative treatment of 
cutaneous metastases from breast cancer [22, 23], and 
orally administered perifosine is in clinical trials for 
the treatment of distinct tumors [23, 24]. The ether 
phospholipid edelfosine (1-O-octadecyl-2-O-methoxy-
rac-glycero-3-phosphocholine), considered as the APL 
prototype, is a rather selective antitumor drug [25-27] 
that preferentially accumulates in tumor cells [25, 26, 
28, 29], and promotes apoptosis in a wide number of 
both hematological and solid tumor-derived cancer cells 
through lipid raft reorganization, leading to the activation 
of the death receptor Fas/CD95 independently of its 
natural ligand FasL/CD95L [26-28, 30-34], or by eliciting 
an endoplasmic reticulum (ER) stress response [34-36]. 
Because edelfosine is a potent inducer of apoptosis in 
cancer cells, we analyzed whether this proapoptotic ether 
lipid drug could be a promising active drug in the search 
of drugs targeting apoptosis in this pediatric cancer. Thus, 
we investigated the in vitro and in vivo action of this drug 
on ES cells as well as its underlying mechanism of action. 
In this work, we show both in vitro and in vivo evidence 
for the anti-ES activity of edelfosine, promoting apoptosis 
through the accumulation of edelfosine in the ER, leading 
to an ER stress response.
RESULTS
Edelfosine is the most active APL in promoting 
apoptosis in ES cells
Previous in vivo and tissue distribution assays 
conducted in mice have shown that the pharmacologically 
effective concentration of edelfosine in plasma is in 
the 10-20 μM range [28, 29, 37]. Thus, we analyzed a 
time-course analysis of the ability of the most clinically 
relevant APLs (edelfosine, perifosine, miltefosine and 
erucylphosphocholine) to induce apoptosis in human 
CADO-ES1 and RD-ES Ewing’s sarcoma cell lines 
when used at 10 μM. We found that edelfosine was the 
most active APL in eliciting an apoptotic response in 
both CADO-ES1 and RD-ES cells in a time-dependent 
manner (Figure 1A and 1B). Edelfosine was the only 
APL that induced a potent apoptotic response after 24 h, 
while the other APLs required longer incubation times 
(Figure 1B). APLs ranked edelfosine > perifosine > 
erucylphosphocholine > miltefosine for their capacity to 
promote apoptosis in ES cells (Figure 1B). We also found 
that the structurally related inactive edelfosine analog 
1-O-octadecyl-rac-glycero-3-phosphocholine (ET-18-
OH) [25, 38], in which the methoxy group in the sn-2 
position of the edelfosine molecule was replaced by an 
OH group, was unable to trigger apoptosis in both ES cell 
lines (Figure 1C and 1D), indicating that the proapoptotic 
activity of edelfosine was highly dependent on its specific 
chemical structure. Because edelfosine was the most active 
APL against ES cells, we further analyzed the underlying 
mechanism of action for the anti-ES activity of edelfosine.
We also found that edelfosine induced a very 
weak autophagic response in ES cells, as assessed 
by the small rate of conversion of LC3 from the 
unconjugated form (LC3-I), which is in the cytosol, to 
the phosphatidylethanolamine-conjugated form (LC3-
II) that binds to the autophagosomal membrane, as well 
as by the negligible effect on the BECN1 protein level 
(Supplementary Figure S1A). Inhibition either at the early 
or late stages of autophagy by using wortmannin and 
chloroquine, respectively, hardly affected the edelfosine-
induced apoptotic response, with only a small, statistically 
nonsignificant increase in apoptosis in both CADO-ES1 
and RD-ES cells (Supplementary Figure S1B). These 
data suggest that edelfosine mainly induces a potent 
apoptotic response in ES cells with only a minor induction 
of autophagy that had no consequences in the cell death 
response.
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Figure 2: Differential induction of apoptosis in osteoblasts and ES cancer cells by edelfosine. Human hFOB 1.19 osteoblasts 
and CADO-ES1 cancer cells were incubated with different concentrations of edelfosine for 24 h, and then apoptosis was evaluated as the 
percentage of cells in the sub-G1 region (hypodiploidy) analyzed by flow cytometry. The sub-G1 region is indicated in each DNA histogram, 
as well as the percentage of apoptosis induced after each treatment. Representative cell cycle profiles of three independent experiments are 
shown.
Figure 1: Induction of apoptosis by edelfosine and structurally related compounds in human ES cell lines. A. Cell 
cycle profiles. DNA content of fixed, propidium iodide-stained cells was analyzed by flow cytometry. CADO-ES1 and RD-ES cells were 
incubated in the absence (Control) or presence of 10 µM of different APLs (edelfosine, EDLF; perifosine, PERIF) for 24 h, and then 
apoptosis was quantified as the percentage of cells in the sub-G1 region (hypodiploidy) analyzed by flow cytometry. The percentage of cells 
with a DNA content less than G1 (sub-G1) is indicated in each histogram. Cell cycle profiles shown, with the sub-G1 population indicated, 
are representative of three experiments performed. B. CADO-ES1 and RD-ES cells were incubated in the absence (Control) or presence 
of 10 µM of different APLs (edelfosine, EDLF; perifosine, PERIF; miltefosine, MILTEF; erucylphosphocholine, ERPC) for the indicated 
times, and the percentage of apoptosis was evaluated as the percentage of cells in the sub-G1 region (hypodiploidy) analyzed by flow 
cytometry. Data shown are means ± SD of three independent experiments. C. CADO-ES1 and RD-ES cells were untreated (Control) or 
treated with the inactive edelfosine analog ET-18-OH (10 µM) for 24 h, and the percentage of apoptosis was evaluated as the percentage 
of cells in the sub-G1 region (hypodiploidy) analyzed by flow cytometry. Representative cell cycle profiles of three experiments performed 
are shown, with the sub-G1 population indicated. The percentage of cells with a DNA content less than G1 (sub-G1) is indicated in each 
histogram. D. Cells were untreated (Control) or treated with 10 µM edelfosine (EDLF) or the inactive edelfosine analog ET-18-OH for 24 
h, and then apoptosis was determined as above. Data shown are means ± SD of three independent experiments.
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ES cancer cells are more sensitive to edelfosine 
than non-transformed human osteoblasts
We next analyzed the proapoptotic activity of 
edelfosine on human hFOB 1.19 osteoblasts, which have 
been widely used as a model of normal osteoblasts. The 
hFOB 1.19 cell line was established by stable transfection 
of fetal bone-derived osteoblast cells with a temperature-
sensitive mutant of the SV40 T antigen [39]. hFOB 
1.19 cells exhibit the matrix synthetic properties of 
differentiated osteoblasts, and are immortalized but non-
transformed human osteoblasts. This cell line is considered 
to be an excellent model for the study of normal osteoblast 
biology in vitro [40]. We found that higher concentrations 
of edelfosine were required to induce apoptosis in hFOB 
1.19 cells as compared to CADO-ES1 ES cells (Figure 2), 
thus indicating that ES tumor cells were more sensitive 
to edelfosine proapoptotic action than non-transformed 
osteoblasts. Interestingly, CADO-ES1 cancer cells seem 
to be especially sensitive to edelfosine, and very low 
concentrations of edelfosine (2.5-5 µM) were sufficient to 
trigger apoptosis (Figure 2). 
Edelfosine induces a caspase-mediated apoptotic 
response in ES cells
We next characterized the apoptotic cell death 
induced by edelfosine in ES cells by using several bona 
fide markers of apoptosis. Cell cycle analyses by flow 
cytometry showed that edelfosine treatment rendered 
Figure 3: Caspase-dependent apoptosis in edelfosine-treated ES cells. A. CADO-ES1 and RD-ES cells were incubated in the 
presence of 10 µM edelfosine for 24 h, and the percentages of cells at the distinct sub-G1 (hypodiploidy, apoptosis), G0/G1, S and G2/M 
phases were calculated by flow cytometry. Cell cycle profiles shown, with the distinct cell cycle phases indicated, are representative of 
three experiments performed. B. ES cells were treated with 10 µM edelfosine at the indicated incubation times, and the percentage of cells 
in each phase of cell cycle was quantitated by flow cytometry. Data shown are means ± SD of three independent experiments. C. RD-ES 
cells were untreated (0 h) or treated with 10 µM edelfosine at the indicated times, and then analyzed for DNA fragmentation in agarose 
gels. A 123-bp DNA ladder was used as standard (Std). Data shown are representative of three experiments performed. D. ES cells were 
incubated in the absence (0 h) or presence of 10 µM edelfosine for the times shown, and then cells were analyzed by immunoblotting with 
antibodies directed against the indicated proteins. β-Actin was used as a loading control. Data shown are representative of three experiments 
performed. E. Colorimetric measurement of caspase-3 activity following incubation of ES cells with 10 µM edelfosine for the indicated 
incubation times. Results show one representative experiment of three experiments performed in triplicate. F. ES cells, untreated (Control) 
or pre-treated with caspase inhibitors z-VAD-fmk or Ac-DEVD-CHO (50 µM) for 1 h, and then incubated without or with 10 µM edelfosine 
(EDLF) for 24 h, were analyzed for apoptosis by flow cytometry. Data shown are means ± SD of three independent experiments. *, P < 
0.05; **, P < 0.01, Student’s t-test.
Oncotarget14600www.impactjournals.com/oncotarget
an increase in the sub-G1 cell population, representing 
apoptotic cells, whereas the cell cycle phases S and G2/M 
were not significantly affected (Figures 3A and 3B). The 
apoptotic response induced by edelfosine was detected 
after only 9-15 h incubation in both ES cell lines (Figure 
3B). This apoptotic response, detected by the appearance 
of a sub-G1 population in cell cycle analysis, which is 
indicative of DNA degradation, was further supported 
by the internucleosomal DNA degradation detected after 
9 h incubation with 10 µM edelfosine (Figure 3C). In 
addition, we found that edelfosine induced caspase-3 and 
-7 activation, as assessed by cleavage of procaspase-3 
and -7 into their respective p20 active forms, as well as 
by proteolysis of the caspase-3 and -7 substrate 116 kDa-
Figure 4: ER drug localization, ER stress and intracellular free calcium level in edelfosine-treated ES cells. A. CADO-
ES1 cells were transfected with erRFP plasmid to visualize ER (red fluorescence) and then incubated with 10 µM Et-BDP-ET (green 
fluorescence). Cells were also stained for nuclei with DAPI (blue fluorescence). Areas of colocalization between ER and Et-BDP-ET 
in the merge panels are yellow. B. ES cells, untreated (0 h) or treated with 10 µM edelfosine for the indicated times, were analyzed by 
Western blot using specific antibodies for the indicated proteins. β-Actin was used as a loading control. Data shown are representative of 
three experiments performed. C. Cell cycle profiles. CADO-ES1 and RD-ES cells, untreated (Control) or pre-treated with 5 µM z-LEVD-
fmk (caspase-4 inhibitor) for 1 h, and then incubated without or with 10 µM edelfosine (EDLF) for 24 h, were analyzed for apoptosis 
by flow cytometry, and then the percentage of apoptosis was evaluated as the percentage of cells in the sub-G1 region (hypodiploidy) as 
in Figure 1A. Cell cycle profiles shown, with the sub-G1 population indicated, are representative of three experiments performed. D. ES 
cells, untreated (Control) or pre-treated with 5 µM z-LEVD-fmk (caspase-4 inhibitor) for 1 h, and then incubated without or with 10 µM 
edelfosine (EDLF) for 24 h, were analyzed for apoptosis by flow cytometry. Data shown are means ± SD of three independent experiments. 
**, P < 0.01, Student’s t-test. E. CADO-ES1 cells were untreated (Control) or treated with 10 μM edelfosine (EDLF) for 3 h followed by 
incubation with Fluo-4 and subsequent analysis by fluorescence microscopy. DIC, differential interference contrast. F. CADO-ES1 cells 
were treated with 10 μM edelfosine for the indicated times, then incubated with Fluo-4, and fluorescence intensity was measured by flow 
cytometry. Data shown are means ± SD of three independent experiments. G. CADO-ES1 cells were preincubated without or with 10 μM 
BAPTA-AM for 1 h, and then treated with 10 μM edelfosine (EDLF) for 18 h and analyzed by flow cytometry to evaluate apoptosis. Data 
shown are means ± SD of three independent experiments. *, P < 0.05, Student’s t-test.
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poly(ADP-ribose) polymerase (PARP) into the 85-kDa 
cleaved form of PARP in CADO-ES1 and RD-ES cells 
(Figure 3D). This caspase activation was detected at early 
incubation times in both ES cell lines, namely about 6 h 
incubation as assessed by Western blot (Figure 3D) and 
about 3 h incubation as estimated by colorimetric assays 
(Figure 3E). The pan-caspase inhibitor z-VAD-fmk as 
well as the caspase-3 inhibitor Ac-DEVD-CHO drastically 
inhibited the apoptotic death of ES cells induced by 
edelfosine (Figure 3F).
Edelfosine accumulates in the ER and induces ER 
stress in ES cells
Next, we analyzed the intracellular location of 
edelfosine in ES cells. To this aim, we used the fluorescent 
edelfosine analog 1-O-[11’-(6’’-ethyl-1’’,3’’,5’’,7’’-
tetramethyl-4’’,4’’-difluoro-4’’-bora-3a’’,4a’’-diaza-
s-indacen-2’’-yl)undecyl]-2-O-methyl-rac-glycero-3-
phosphocholine (Et-BDP-ET) that has been previously 
reported to be a reliable analog to visualize the subcellular 
localization of the drug [35, 41, 42]. Et-BDP-ET was 
predominately located in the ER of CADO-ES1 cells 
(Figure 4A), as assessed by using a version of red 
fluorescence protein targeted to the ER lumen (ER-
targeted red fluorescence protein), which completely 
colocalized with the ER marker calreticulin [43]. We also 
found that edelfosine induced an ER stress response in 
both CADO-ES1 and RD-ES cell lines, as assessed by 
a number of ER stress markers (Figure 4B), including 
caspase-4 activation (cleavage of procaspase-4 into its 
p20 active form), CHOP/GADD153 upregulation, eIF2α 
phosphorylation, and cleavage of Bap31 into the 20-kDa 
fragment that acts as a linker of proapoptotic signals 
between ER and mitochondria [44]. Phosphorylation of 
eIF2α was detected after only 3-h incubation (Figure 4B), 
suggesting that edelfosine elicits rapidly an ER stress 
response. However, the protein level of GRP78, a major 
ER chaperone that promotes tumor cell survival [45], was 
not affected following edelfosine treatment (Figure 4B). 
Preincubation with the caspase-4 inhibitor z-LEVD-fmk 
prevented edelfosine-induced apoptosis (Figure 4C and 
4D). Because ER is a key subcellular structure for Ca2+ 
storage and for the control of intracellular free Ca2+ levels, 
we examined the effect of edelfosine on intracellular 
Ca2+ levels in ES cells by using the intracellular free Ca2+ 
indicator Fluo-4 [46]. Edelfosine treatment increased 
the intracellular free Ca2+ level as detected by confocal 
microscopy and flow cytometry (Figure 4E and 4F). 
Intracellular Ca2+ chelation with BAPTA (1,2-bis(2-
aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid) led 
to a modest, but statistically significant, reduction of 
the edelfosine-induced apoptotic response (Figure 4G). 
Taken together, these data suggest that edelfosine induces 
apoptosis through an ER stress response in ES cells.
Mitochondrial involvement in edelfosine-induced 
apoptosis in ES cells
Following ER stress response induced by edelfosine, 
we found Bap31 cleavage, leading to the generation of 
the 20-kDa fragment (Figure 4B) that acts as a signal 
transmitter between ER and mitochondria [44, 47]. 
On these grounds, we examined the putative role of 
mitochondria in the killing action of edelfosine on ES 
cells. Caspase-9 was activated by the time apoptosis 
was triggered, as assessed by Western blot (Figure 5A), 
showing the cleavage of 47 kDa-procaspase-9 into 
the active 35-38-kDa fragment, and by colorimetric 
measurements (Figure 5B). Preincubation with the 
caspase-9 inhibitor z-LEHD-fmk prevented edelfosine-
induced apoptosis (Figure 5C). Edelfosine treatment 
resulted in a rapid activation of the proapoptotic 
protein Bax, detected by using an anti-Bax (clone 6A7) 
monoclonal antibody that recognized the active form of 
Bax (Figure 5A). However, the levels of the antiapoptotic 
proteins Bcl-2 and Bcl-XL were hardly affected (Figure 
5A). We also found a rapid release of cytochrome c 
from the mitochondria into the cytosol (Figure 5A). 
Edelfosine induced the generation of reactive oxygen 
species (ROS) as well as mitochondrial transmembrane 
potential (ΔΨm) dissipation, as assessed by the conversion 
of dihydroethidium (DHE) into ethidium (Eth) (red 
fluorescence) and the loss of 3,3´-dihexyloxacarbocyanine 
iodide [DiOC6(3)] fluorescence (green fluorescence), 
respectively, in both CADO-ES1 and RD-ES cells 
(Figure 5D). The generation of ROS was rather prominent 
following incubation of ES cells with edelfosine (Figure 
5D and 5E), and pretreatment of ES cells with the 
antioxidant butylated hydroxyanisole (BHA) inhibited 
edelfosine-induced apoptosis (Figure 5F), suggesting a 
role for ROS generation in the killing process.
Involvement of c-Jun amino terminal kinase 
(JNK), but not extracellular-signal-regulated 
kinase (ERK), in edelfosine-induced apoptosis in 
ES cells
ASK-1/JNK signaling has been implicated in ER-
induced apoptosis [48]. Here, we found that edelfosine 
induced a potent and persistent activation of JNK in both 
CADO-ES1 and RD-ES cells, as assessed by a solid-
phase kinase assay, using a fusion protein between GST 
and c-Jun (amino acids 1–223) as a substrate of JNK, as 
well as by Western blot for JNK phosphorylation (Figure 
6A, upper). Using both techniques we found a very rapid 
activation of JNK after 3 h incubation, thus suggesting that 
this response was an early event following treatment of ES 
cells with edelfosine. Preincubation with the specific JNK 
inhibitor SP600125 highly reduced the edelfosine-induced 
apoptotic response in both CADO-ES1 and RD-ES cells 
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(Figure 6A, lower). Edelfosine treatment also induced 
ERK phosphorylation in both ES cell lines (Figure 6B, 
upper), but preincubation with the ERK inhibitor U0126 
did not significantly affect the apoptotic response induced 
by edelfosine (Figure 6B, lower), even though U0126 by 
itself promoted a slight increase in apoptosis, particularly 
in CADO-ES1 cells (Figure 6B, lower).
In vivo antitumor effect of edelfosine in ES 
xenografts
We next evaluated the in vivo antitumor activity 
of orally administered edelfosine in an ES xenograft 
animal model. In agreement with previous studies [35], 
we found that daily doses of 30 mg/kg and 40 mg/
kg edelfosine were well tolerated, 45 mg/kg being 
Figure 5: Involvement of mitochondrial-mediated signaling in edelfosine-induced apoptosis in ES cells. A. Cells were 
untreated (0 h) or treated with 10 µM edelfosine for the times shown, and then cells were analyzed by immunoblotting with antibodies 
directed against the indicated proteins. β-Actin was used as a loading control. Cytochrome c was analyzed in the cytosolic fraction isolated 
as previously described [73]. Data shown are representative of three experiments performed. B. Colorimetric measurement of caspase-9 
activity following incubation of ES cells with 10 µM edelfosine for the indicated incubation times. Results shown are representative of 
three experiments performed in triplicate. C. ES cells, untreated (Control) or pre-treated with 50 µM µM z-LEHD-fmk (caspase-9 inhibitor) 
for 1 h, and then incubated without or with 10 µM edelfosine (EDLF) for 24 h, were analyzed for apoptosis by flow cytometry. Data shown 
are means ± SD of three independent experiments. **, P < 0.01, Student’s t-test. D. CADO-ES1 and RD-ES cells were incubated for 6 
h in the absence (Control) or in the presence of 10 µM edelfosine (EDLF) and then analyzed for ΔΨm disruption [DiOC6(3)
low] and ROS 
generation (DHE→Eth) by flow cytometry. Data shown are representative of three experiments performed. E. ES cells were treated with 10 
µM edelfosine (EDLF) for the indicated times, and percentages of cells with disrupted ΔΨm [DioC6(3)
low] and generating ROS (DHE→Eth)
high were measured. Data shown are means ± SD of three independent experiments. F. CADO-ES1 cells, untreated (Control) or pretreated 
with 50 µM BHA for 1 h, and then incubated without or with 10 µM EDLF for 24 h, were analyzed for apoptosis by flow cytometry. Data 
shown are means ± SD of three independent experiments. **, P < 0.01, Student’s t-test.
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the maximum tolerated dose of edelfosine, in CB17-
severe combined immunodeficient (SCID) mice. These 
mice were inoculated with 5 x 106 CADO-ES1 cells. 
When tumors were palpable, mice were randomly 
assigned to three cohorts of seven mice each, receiving 
a daily oral administration of 30 mg/kg edelfosine, 40 
mg/kg edelfosine, and vehicle (water). Serial caliper 
measurements were done at the indicated times to 
calculate the approximate tumor volume until mice were 
killed after a 3-week treatment (Figure 7A). Animals were 
Figure 6: JNK and ERK activation in edelfosine-treated ES cells. A. (upper) CADO-ES1 and RD-ES cells, untreated (0 h) or 
treated with 10 µM edelfosine for different times, were analyzed for JNK activation using a solid-phase JNK assay (migration position of 
GST-c-Jun-1-223 is indicated) and immunoblotting with antibodies directed against the indicated phosphorylated (p-JNK) (54 kDa, JNK2; 
46 kDa, JNK1) and nonphosphorylated (JNK2) JNK proteins. (lower) ES cells, untreated (Control) or pretreated with 20 µM SP600125 for 
1 h, and then incubated without or with 10 µM EDLF for 24 h, were analyzed for apoptosis by flow cytometry. Data shown are means ± 
SD (lower) or representative (upper) experiments of three performed. *, P < 0.05; **, P < 0.01, Student’s t-test. B. (upper) CADO-ES1 and 
RD-ES cells, untreated (0 h) or treated with 10 µM edelfosine for different times, were analyzed for ERK1/2 activation by immunoblotting 
with antibodies directed against the indicated phosphorylated (p-ERK) (44 kDa, ERK1; 42 kD, ERK2) and nonphosphorylated (ERK2) 
ERK proteins. (lower) ES cells, untreated (Control) or pretreated with 10 µM U0126 for 1 h, and then incubated without or with 10 µM 
EDLF for 18 h, were analyzed for apoptosis by flow cytometry. Data shown are means ± SD (lower) or representative (upper) experiments 
of three performed. *, P < 0.05, Student’s t-test.
Oncotarget14604www.impactjournals.com/oncotarget
killed for ethical reasons when tumor size reached ~10% 
of body weight, and this size was approximately reached 
by 3 weeks time from the start of treatment in the ES 
tumor-bearing mice (Figure 7A). A comparison of tumors 
isolated from untreated control and drug-treated CADO-
ES1-bearing mice, at the end of the treatment, rendered a 
remarkable anti-ES activity of edelfosine (Figure 7B and 
7C), with a statistically significant reduction in both tumor 
weight and volume (Figure 7B). The 30 mg/kg edelfosine 
treatment rendered a reduction of 73% and 75% in tumor 
weight and volume respectively, whereas the treatment of 
40 mg/kg edelfosine led to a reduction of 77% and 86% 
in tumor weight and volume respectively (Figure 7B). No 
morphological alterations were observed in the organs 
of drug-treated mice as compared to drug-free control 
animals, indicating no apparent toxicity. Likewise, no 
Figure 7: In vivo antitumor activity of edelfosine on human ES xenografts. A. CB17-SCID mice were inoculated subcutaneously 
with CADO-ES1 cells. Oral administration of edelfosine (30 and 40 mg/kg, once-daily dosing regimen) and water vehicle (Control) started 
in parallel after the development of a palpable tumor in tumor-bearing mice (n = 7). Caliper measurements of each tumor were carried out 
at the indicated times. Data shown are means ± SD (n = 7). B. After completion of the in vivo assays, control drug-free mice and animals 
treated with 30 and 40 mg/kg edelfosine were sacrificed and tumor weight and volume were measured. Data shown are means ± SD (n = 7). 
*, P < 0.05; **, P < 0.01, Student’s t-test. C. A remarkable ES tumor growth inhibition was observed after edelfosine treatment in CADO-
ES1-bearing SCID mice. Representative tumors isolated from drug-free CADO-ES1-bearing mice (Control) and the two experimental 
groups of drug-treated pancreatic tumor-bearing mice (EDLF) are shown. D. Edelfosine induces apoptosis and ER stress response in ES 
tumor xenografts. Light microscopic and immunohistochemical examination (x200 magnification) of xenograft tumors were performed 
in tumor-bearing drug-free SCID mice (Control) and animals treated with 30 mg/kg edelfosine (EDLF). Tissue sections of tumors were 
stained with hematoxylin and eosin (H&E), showing the presence of irregular and medium-sized giant cells with eosinophilic cytoplasm 
and pyknotic nuclei (arrow), indicative of cell death by apoptosis, following edelfosine treatment. Proliferative cells were observed in 
tumor tissue from drug-free animals following Ki67 staining, whereas the tumor sections of edelfosine-treated animals showed lack of 
staining. Treatment of CADO-ES1 tumor-bearing mice with edelfosine resulted in increased tumor apoptosis as detected by activated 
caspase-3 staining. Cleaved caspase-3-positive cells (arrow) were observed in edelfosine-treated mice tumors, while no staining was 
detected in drug-free animals. Positive staining for GADD153 is shown as dark coloring of the cell nucleus (arrow) in the edelfosine-treated 
tumor. Images shown are representative of at least four independent experiments.
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Figure 8: The combination of edelfosine with different antitumor agents potentiates apoptosis in ES cells. CADO-ES1 cells 
were incubated for 24 h with 2.5 µM edelfosine (EDLF), 1 nM vincristine (VINC), 1 nM doxorubicin (DOX), 500 µM cyclophosphamide 
(CPD), 100 µM metformin (MET) or the combination of edelfosine with the above agents. Untreated control cells were run in parallel. 
Apoptosis was determined by flow cytometry as the percentage of hypodiploid (sub-G1) cells following cell cycle analysis. The percentage 
of cells with a DNA content less than G1 (sub-G1) is indicated in each histogram. Cell cycle profiles shown, with the sub-G1 population 
indicated, are representative of three experiments performed. 
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significant differences in body weight were found between 
drug-treated and untreated control animals (less than 3% 
of body weight loss in drug-treated vs. control cohorts).
In vivo identification of apoptosis and ER stress 
in ES tumors following edelfosine oral treatment
Histological patterns of tumors isolated from 
control drug-free tumor-bearing animals revealed a 
relative uniformity in cell size and morphology, including 
the nuclear morphology. In contrast, examination of 
hematoxylin and eosin-stained sections of tumors from 
mice orally treated with edelfosine showed the presence 
of irregular, large and medium-sized giant cells with 
eosinophilic cytoplasm and pyknotic nuclei (Figure 7D). 
The nuclei in dying cells displayed nuclear fragmentation 
characteristic of cell death by apoptosis (Figure 7D). A 
strong cell proliferation activity, as assessed by Ki67 
staining, was determined in the tumors isolated from 
the control drug-free group (Figure 7D), but no cell 
proliferation was detected in the tumor xenografts from 
the edelfosine-treated group (Figure 7D). The anti-
activated caspase-3-specific antibody selectively labeled 
the cytoplasm of apoptotic cells in tumors from drug-
treated mice, while no staining was observed in the 
control drug-free group (Figure 7D). Upregulation of the 
ER stress-associated marker CHOP/GADD153, indicating 
an ER stress response, was visualized in the ES tumors 
isolated from edelfosine-treated mice, but not from control 
drug-free mice (Figure 7D). These results indicate that 
edelfosine treatment induces ER stress and apoptosis in 
the ES tumors in vivo.
Combination of edelfosine with drugs in clinical 
use for ES potentiates apoptosis
We next analyzed the putative potentiation of 
apoptosis as a result of combining edelfosine with 
additional drugs used in the clinics for ES treatment and 
acting through different mechanisms of action. Current 
standard chemotherapy includes vincristine, doxorubicin, 
and cyclophosphamide, also known as VDC, alternating 
with ifosfamide and etoposide [49, 50]. As shown in 
Figure 8, we found that the combination of edelfosine with 
vincristine, doxorubicin or cyclophosphamide potentiated 
the proaptototic effect of edelfosine in CADO-ES1 
cancer cells. Vincristine as well as other microtubule-
damaging agents suppress microtubule dynamics, leading 
to disruption of the mitotic spindle in dividing cells, cell 
cycle arrest and apoptosis [51, 52], whereas doxorubicin 
and cyclophosphamide act through DNA interaction [53, 
54]. Because edelfosine does not target DNA, but acts at 
the cell membrane level [18, 33, 34], this drug is a good 
candidate for the combination with the above antitumor 
drugs in order to improve therapeutic regimens for the 
treatment for this pediatric cancer. Interestingly, we 
have also found that the combination of metformin and 
edelfosine also potentiates apoptosis in CADO-ES1 cells 
(Figure 8). Metformin is the most commonly prescribed 
drug for type 2 diabetes mellitus, but it is now emerging as 
an attractive candidate for cancer prevention and treatment 
[55].
DISCUSSION
The results reported here show for the first time the 
antitumor activity of the ether phospholipid edelfosine 
against ES cells, and point out the involvement of ER 
as a target in ES therapy. Edelfosine induces caspase-
dependent apoptotic cell demise in ES cells that is mainly 
mediated by targeting ER and involves ER stress and 
mitochondrial-mediated processes. Our data indicate that 
edelfosine is the most potent APL in eliciting an apoptotic 
response in ES cells. Among the most clinically relevant 
APLs, we found that these compounds ranked edelfosine 
> perifosine > erucylphosphocholine > miltefosine for 
their capacity to promote apoptosis in ES cells. Edelfosine 
induced a remarkable apoptotic activity in ES cells when 
used at the low micromolar range (5-10 µM), which fits 
well with the steady-state plasma levels of edelfosine (10-
20 µM) found in a number of animal model in vivo assays 
[28, 29, 37]. In addition, ES cancer cells seem to be rather 
sensitive to edelfosine, as apoptosis was triggered upon 
incubation with very low concentrations of edelfosine 
(2.5-5 µM). The fact that ES tumor cells were more 
sensitive to edelfosine than the non-transformed hFOB 
1.19 osteoblast cell line is in agreement with previous 
reports showing a rather selective proapoptotic action of 
edelfosine on tumor cells [25-27].
Figure 9 depicts a schematic model of a putative 
mechanism of action for edelfosine-induced apoptosis 
in ES cells. Edelfosine accumulates in the ER where it 
triggers an ER stress response, leading to caspase-4 
activation, CHOP/GADD153 upregulation, eIF2α 
phosphorylation, increase in intracellular free Ca2+ level, 
and cleavage of Bap31 into the 20-kDa fragment, which 
directs proapoptotic signals between ER and mitochondria 
[44]. Mitochondria seem to be critical in the apoptotic 
outcome in edelfosine-treated ES cells, leading to Bax 
and caspase-9 activation, ΔΨm dissipation, release of 
cytochrome c to the cytosol, and ROS generation. 
Caspase-9 could be activated by either ER-related 
caspase-4 activation [56] or apoptosome formation 
through the binding of cytochrome c to apoptosis protease-
activating factor-1 [57]. Inhibition of caspase-4, caspase-9 
and ROS generation blocked edelfosine-induced apoptosis, 
highlighting the essential role of ER and mitochondria in 
edelfosine-induced apoptosis in ES cells. The generation 
of ROS is suggested to lead to the acquisition of apoptosis-
promoting conditions, thus facilitating the triggering of 
an apoptotic response. Increased intracellular free Ca2+ 
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level seems to play a role, but likely not an essential 
one, in edelfosine-induced cell demise, as Ca2+ chelation 
inhibits, but does not totally block, apoptosis. JNK was 
persistently activated during incubation of ES cells with 
edelfosine, and JNK inhibition prevented edelfosine-
induced apoptosis, suggesting a major role for JNK in the 
proapoptotic action of edelfosine on ES cells, in a similar 
way as previously found for the proapoptotic action of 
edelfosine in leukemic [38] and pancreatic [35] cancer 
cells. Thus, JNK seems to be a critical signaling pathway 
in the proapoptotic action of edelfosine in cancer cells.
 The results reported here represent the first 
study on the action of APLs in ES and demonstrate 
the potent proapoptotic in vitro and in vivo anti-ES 
activity of edelfosine. In addition, the upregulation of 
CHOP/GADD153 in the xenograft tumors that undergo 
apoptosis following edelfosine oral treatment of ES 
tumor-bearing mice further supports the in vivo ER stress 
response induced by edelfosine in this tumor. Perifosine 
has been recently found to induce apoptosis in human 
osteosarcoma cells [58]. A phase II study of daily oral 
perifosine in patients with advanced soft tissue sarcoma 
showed prolonged responses in heavily pretreated patients, 
even though the primary objective of ≥40% 6-month 
progression-free survival rate was not achieved, with 
grade 1 to 2 gastrointestinal toxicity or fatigue being the 
most common ( > 50% of patients) toxicities observed 
[59]. In contrast, another phase II study involving adult 
patients with locally advanced or metastatic inoperable 
soft tissue sarcoma did not show evidence of activity 
[60]. Our data suggest that edelfosine shows a higher 
anti-ES activity than perifosine, and previous animal 
model studies have shown the lack of significant toxicity 
following orally administered edelfosine [28, 29, 61], 
including lack of cardiotoxicity, hepatotoxicity or renal 
toxicity [61]. Our present study on the in vitro and in vivo 
actions of edelfosine on ES, together with the effective in 
vivo antitumor action of this APL on several additional 
tumors, such as pancreatic cancer [35], multiple myeloma 
[28], mantle lymphoma [29] and chronic lymphoblastic 
lymphoma [29], warrants further studies on the putative 
use of edelfosine as a promising antitumor drug lacking 
significant toxicity.
Interestingly, the herein reported potentiation 
of proapoptotic activity following combination of 
edelfosine with several anticancer drugs currently used 
for ES treatment suggests that edelfosine could be a 
promising candidate for the use of combination therapy 
in this disease. The results reported here suggest that 
the combined use of edelfosine, acting at the membrane 
Figure 9: Schematic model of ER involvement in edelfosine-induced apoptosis in ES cancer cells. This is a schematic 
diagram designed to portray one currently plausible mechanism of how edelfosine induces apoptosis via ER stress in ES tumor cells. 
Edelfosine accumulates in the ER, inducing an ER stress response that leads to cell death. See text for details.
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level, with drugs targeting microtubules (vincristine) or 
DNA (doxorubicin, cyclophosphamide) might improve 
the current therapeutic regimens for ES. Furthermore, we 
also found here that the combined treatment of metformin 
and edelfosine also potentiated apoptosis in ES cells. 
Metformin, a well-known insulin-sensitizer commonly 
used for type 2 diabetes therapy that is gaining attention 
in cancer research [62-64], has recently been found to 
inhibit growth and sensitize osteosarcoma cell lines to 
cisplatin [65]. In addition, metformin has been recently 
found to potentiate the efficacy of antitumor drugs against 
different tumor cells [66-70]. Our results have shown that 
the combined treatment of edelfosine and the above drugs 
noticeably potentiated the apoptosis outcome elicited 
by each individual drug in ES cells, thus suggesting 
that edelfosine, as well as its underlying endoplasmic 
reticulum-mediated mechanism of action, might be of 
interest for combination therapy regimens in the treatment 
of this pediatric cancer.
Despite multimodal therapy, consisting of high-
dose chemotherapy, surgery and radiotherapy, survival of 
patients with metastatic or recurrent ES has not improved 
significantly during the past decades. The results reported 
here provide the proof of concept for the anti-ES efficacy 
of edelfosine, and suggest that edelfosine oral treatment 
can become a promising new drug for ES therapy. On 
these grounds, further studies focused on effectively 
translating the herein reported therapeutic benefits in a 
putative clinical setting are warranted. In addition, the 
fact that edelfosine targets ER in ES cells (this report) 
as well as in pancreatic cancer cells [35], leading to ER 
stress-mediated apoptosis, highlights that ER can be a 
promising and valuable target for the design of therapeutic 
strategies and drugs aimed to improve cancer treatment, 
and particularly ES prognosis. 
MATERIALS AND METHODS
Drugs and reagents
Edelfosine was obtained from R. Berchtold 
(Biochemisches Labor, Bern, Switzerland). A stock 
solution was prepared at 2 mM in RPMI-1640 culture 
medium, containing 10% (v/v) fetal bovine serum (FBS), 
by heating at 50°C for 30 min, as previously described 
[25]. Perifosine (octadecyl-(1,1-dimethyl-piperidinio-4-
yl)-phosphate) and erucylphosphocholine ((13Z)-docos-
13-en-1-yl 2-(trimethylammonio)ethyl phosphate) were 
from Zentaris. Miltefosine (hexadecylphosphocholine) 
was from Calbiochem. Stock sterile solutions of the 
distinct APL analogs (2 mM) were prepared in RPMI-
1640 culture medium (Invitrogen), supplemented with 
10% (v/v) heat-inactivated fetal bovine serum (FBS), 
2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/
ml streptomycin (GIBCO-BRL), as above. Caspase-4 
inhibitor z-LEVD-fmk and the pan-caspase inhibitor 
z-VAD-fmk were from Alexis Biochemicals. Caspase-3 
inhibitor Ac-DEVD-CHO, caspase-9 inhibitor z-LEHD-
fmk, and the JNK inhibitor SP600125 were from 
Calbiochem. Acrylamide, bisacrylamide, ammonium 
persulfate, and N,N,N’N’-tetramethylethylenediamine 
were from Bio-Rad. All other chemicals were from Merck 
or Sigma.
Cells and culture conditions
The human ES cell lines CADO-ES1 and RD-ES 
were from the Deutsche Sammlung von Mikroorganismen 
und Zellkulturen GmbH-DSMZ (German Collection 
of Microorganisms and Cell Cultures), and were grown 
in RPMI-1640 supplemented with 10% (v/v) heat-
inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 
and 100 μg/ml streptomycin at 37ºC in humidified 95% 
air and 5% CO2. APLs were added to the cell culture 
at the concentrations and for the times indicated in the 
respective figures. To analyze the effect of the distinct 
caspase and kinase inhibitors used in this study, 2.5 x 105/
ml cells were pretreated with each inhibitor for 1 h before 
edelfosine treatment, and then samples were analyzed by 
flow cytometry to determine apoptosis through cell cycle 
analyses.
Measurement of caspase activity by colorimetric 
methods
Caspase-3 and caspase-9 activities were quantified 
by spectrophotometric detection of chromophore 
(pNA, p-nitroanilide) following its cleavage from the 
labeled substrates Ac-DEVD-pNA and Ac-LEHD-pNA 
(Calbiochem), respectively. ES cell lines were treated with 
10 µM edelfosine during different time periods. Then cells 
were lysed with extract buffer (25 mM HEPES, pH 7.7, 
0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton 
X-100, 20 mM β-glycerophosphate, 0.1 mM Na3VO4), 
containing protease inhibitors (1 mM PMSF, 20 μg/ml 
aprotinin and 20 μg/ml leupeptin) and supplemented with 
2 mM DTT. For the quantification of caspase activity, 25 
and 50 μg protein were used for evaluation of caspase-3 
and caspase 9 activities respectively in 96-well plates. 
Next, extracts were incubated with 100 µM of substrate 
in the reaction buffer (25 mM HEPES, pH 7.4, 10% 
sucrose, 10 mM DTT) for 1 h at 37°C. All reactions 
were performed in triplicate. The samples were read by 
an ELISA spectrophotometer (BioRad) at 405 nm. The 
results are expressed as relative caspase activity, which 
is the ratio between the caspase activity of the sample and 
that measured in control (without treatment).
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Apoptosis assays
Quantification of apoptotic cells was determined by 
flow cytometry as the percentage of cells in the sub-G1 
region (hypodiploidy) in cell cycle analysis as previously 
described [26]. Cell cycle profiles were generated using 
manually drawn gates with Cyflogic software. Apoptosis 
was also assessed by isolation of fragmented DNA and 
subsequent analysis by electrophoresis on 1% agarose 
gels as previously described [25, 71]. A 123-bp DNA 
ladder (Life Technologies) was used as standard. DNA 
was visualized after electrophoresis by ethidium bromide 
staining.
Solid phase JNK assay
A fusion protein between glutathione S-transferase 
(GST) and c-Jun (amino acids 1-223) was used as a 
substrate for JNK as previously described [38, 72]. The 
32P-phosphorylated proteins were resolved in SDS-10% 
polyacrilamide gels followed by autoradiography.
Western blot analysis
5 x 106 cells were lysed with 60 µl of extract 
buffer (25 mM HEPES, pH 7.7, 0.3 M NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 20 mM 
β-glycerophosphate, 0.1 mM Na3VO4) supplemented 
with protease inhibitors (1 mM phenylmethylsulfonyl 
fluoride, 20 µg/ml aprotinin, 20 µg/ml leupeptin). 
Forty five micrograms of proteins were run in SDS 
polyacrylamide gels, transferred to nitrocellulose filters, 
blocked with 5% (w/v) power defatted milk in TBST 
(50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1%Tween 
20) for 90 min at room temperature, and incubated for 
1 h at room temperature or overnight at 4ºC with the 
following specific antibodies: anti-active caspase-3 
rabbit monoclonal antibody (1:1000, BD Pharmingen), 
anti-poly(ADP-ribose) polimerase mouse monoclonal 
antibody (1:1000, BD Pharmingen), anti-caspase-7 mouse 
monoclonal antibody (1:1000, BD Pharmingen), anti-
caspase-9 rabbit polyclonal antibody (1:1000, Oncogene), 
anti-caspase-4 goat polyclonal antibody (1:250, Santa 
Cruz Biotechnology), anti-GADD153 rabbit monoclonal 
antibody (1:250, Santa Cruz Biotechnology), anti-Bap31 
(C-15) goat polyclonal antibody (1:500, Santa Cruz 
Biotechnology), anti-eIF2α rabbit polyclonal antibody 
(1:1000, Cell Signaling Technology), anti-phospho-
eIF2α (Ser51) rabbit monoclonal antibody (1:1000, Cell 
Signaling Technology), anti-GRP78 rabbit monoclonal 
antibody (1:1000, Cell Signaling Technology), anti-Bcl-2 
mouse monoclonal antibody (1:500, BD Pharmingen), 
anti-Bcl-XL monoclonal antibody (1:1000, Cell Signaling 
Technology), anti-p-JNK (Thr183/Tyr185) (98F2) and 
anti-JNK2 rabbit monoclonal antibodies (1:1000, Cell 
Signaling Technology), anti-p- ERK1/2 rabbit polyclonal 
antibody (1:1000, Cell Signaling Technology), anti-
ERK2 mouse monoclonal antibody (1:1000, Santa Cruz 
Biotechnology), anti-LC3 (microtubule-associated protein 
1 light chain 3) rabbit polyclonal antibody (1:1000, Cell 
Signaling Technology), anti-BECN1 (Beclin-1; Bcl-
2 interacting myosin/moesin-like coiled-coil protein 
1) rabbit polyclonal antibody (1:1000, Cell Signaling 
Technology). Signals were developed using an enhanced 
chemoluminescence detection kit (GE Healthcare).
Mitochondrial cytochrome c release
Release of cytochrome c from mitochondria to 
cytosol was analyzed by Western blot of the cytosolic 
fractions as previously described [73], using an anti-
cytochrome c (7H8.2C12) mouse monoclonal antibody 
antibody (1:500, BD Pharmingen).
ER localization of edelfosine
The subcellular localization of edelfosine in the ER 
of ES cells was carried out as previously described [35]. 
5 x 105 cells were transfected with a plasmid encoding 
endoplasmic reticulum-targeted red fluorescence protein 
(erRFP) [43], kindly provided by F. X. Pimentel-
Muinos (Instituto de Biología Molecular y Celular del 
Cáncer, Centro de Investigación del Cáncer, Salamanca, 
Spain), using Lipofectamine 2000 transfection reagent 
(Invitrogen), and then incubated for 1 h with 10 µM 
of the fluorescent edelfosine analog Et-BDP-ET [42], 
kindly provided by F. Amat-Guerri and A. U. Acuña 
(CSIC, Madrid, Spain). Colocalization of the distinct 
fluorochromes was analyzed using a LSM 510 laser scan 
confocal microscope (Carl Zeiss).
Analysis of ΔΨm and ROS generation by flow 
cytometry
To evaluate ΔΨm and ROS generation, 2.5 x 10
5 cells 
were washed once with PBS and then were incubated in 
500 µl PBS with 20 nM DiOC6(3) (green fluorescence) 
(Molecular Probes) and 2 µM DHE (red fluorescence 
after oxidation) (Sigma) for 20 min at 37ºC, followed 
by analysis on a FACSCalibur flow cytometer (Becton 
Dickinson) as previously described [74].
Measurement of intracellular calcium
Cells were incubated with 2 µM Fluo-4 AM dye 
(Molecular Probes) for 30 min at 37ºC, and then analyzed 
by fluorescence microscopy or flow cytometry.
Oncotarget14610www.impactjournals.com/oncotarget
Xenograft mouse models
Animal procedures in this study complied with the 
Spanish (Real Decreto RD1201/05) and the European 
Union (European Directive 2010/63/EU) guidelines on 
animal experimentation for the protection and humane 
use of laboratory animals, and were conducted at the 
accredited Animal Experimentation Facility (Servicio de 
Experimentación Animal) of the University of Salamanca. 
Procedures were approved by the Ethics Committee of 
the University of Salamanca. Female CB17-SCID mice 
(8-week old) (Charles River Laboratories), kept and 
handled according to institutional guidelines, complying 
with Spanish legislation under 12/12 h light/dark cycle 
at a temperature of 22°C, received a standard diet and 
acidified water ad libitum. CADO-ES1 cells (5 × 106) 
were injected subcutaneously in 100 μl phosphate-buffered 
saline together with 100 μl Matrigel basement membrane 
matrix (Becton Dickinson) into the right flank of each 
mouse. When tumors were palpable, approximately 2 
weeks after tumor cell implantation, mice were randomly 
assigned to cohorts of seven mice each, receiving a daily 
oral administration of edelfosine (30 or 40 mg/kg of 
body weight) or an equal volume of vehicle (water). The 
shortest and longest diameter of the tumor were measured 
with calipers at the indicated time intervals, and tumor 
volume (mm3) was calculated using the following standard 
formula: (the shortest diameter)2 × (the longest diameter) 
× 0.5. Animal body weight and any sign of morbidity were 
monitored. Drug treatment lasted 3 weeks. Animals were 
killed 24 h after the last drug administration according to 
institutional guidelines, and then tumors were carefully 
removed, weighed and analyzed. A necropsy analysis 
involving tumors and distinct organs was carried out.
Histochemical analysis
Tumor tissue samples were fixed in 4% buffered 
paraformaldehyde and embedded in paraffin. Tissue 
sections (5 µm) were deparaffinized and hydrated in 
graded ethanol and distilled water. Endogenous peroxidase 
activity was blocked using methanol and 30% H2O2 for 30 
min. Sections were counterstained with hematoxylin and 
eosin (H&E), and then incubated overnight at 4ºC with 
different antibodies: rabbit anti-human Ki67 monoclonal 
antibody (clone SP6) (1:1000 dilution, Abcam), anti-
active human caspase-3 (1:100 dilution) rabbit polyclonal 
antibody that specifically recognized the active ~20-kDa 
subunit (Cell Signaling Technology), or with F-168 anti-
human CHOP/GADD153 (1:50 dilution) rabbit polyclonal 
antibody (Santa Cruz Biotecnology). After washing with 
PBS, sections were incubated with biotinylated anti-
rabbit IgG antibody (BD Pharmingen) for 60 min at room 
temperature and washed with PBS. Then, sections were 
incubated with streptavidin horseradish-peroxidase (Vector 
Laboratories) for 60 min in a moist chamber, washed with 
PBS, and sites of peroxidase activity were visualized using 
3,3´-diaminobenzidine tetrahydrochloride solution (DAB). 
Sections were subsequently counterstained with Mayer’s 
hematoxylin or Light Green. Staining was analyzed with a 
Nikon Eclipse 400® microscope and Metamorph® software 
(Molecular Devices Corporation).
Statistical analysis
Results are shown as means ± S.D. of the number 
of experiments indicated. Statistical evaluation was 
performed by Student’s t-test. A P-value of < 0.05 was 
considered statistically significant.
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